About
Randall Moreadith joined Serina Therapeutics in September 2010 as Chief Executive Officer. Prior to joining Serina, Dr. Moreadith, 56, was Chief Development Officer at Nektar Therapeutics where he built a clinical and drug development program that successfully moved several of the company's PEGylated small molecule drugs into the clinic, including the launch of NKTR-102 into four clinical indications (ovarian, breast, cervical and colorectal cancer). He was formerly the Executive Vice President and Chief Medical Officer of Cardium Therapeutics where he led the advancement of novel DNA-based therapeutics into Phase 2b and Phase 3 late-stage development. Before Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. where he led the Clinical, Regulatory and Quality Assurance Groups. Prior to that, Dr. Moreadith was co-Founder, President and Chief Operating Officer of ThromboGenics Ltd., a leader in the field of thrombosis drug development. During his tenure at ThromboGeni
Position in the VCSift Database
- • 2 investors at Serina Therapeutics are tracked.
- • 76 investors hold the President and Chief Executive Officer role in VCSift. Randall Moreadith is one of them.
- • 28 investors are based in Huntsville, Alabama, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Huntsville, US
Contact Information
Find more investors like Randall
Search Investors